Human papillomavirus infection and cervical cancer in HIV+ women

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Human papillomavirus (HPV) is the first identified necessary cause of human cancers and is associated with nearly 100% of all cervical cancers. Compared to the general female populations, HIV+ women have higher prevalence and incidence of cervical HPV infections, higher risks of persistent HPV infections and subsequent cervical intraepithelial lesions, and a higher incidence of cervical cancer. Although the wide use of combined antiretroviral therapy (cART) has improved the immune function and the longevity of HIV+ women, the incidence of cervical cancer in HIV+ women has not declined. For HIV+ women who follow routine cervical cancer screenings, their incidence of cervical cancer is comparable to that in HIV-negative women. Thus, adherence to the recommended cervical cancer screening is still critical for HIV+ women to prevent cervical cancer. Prophylactic HPV vaccines may also benefit HIV+ women, but prospective studies are needed to determine the effectiveness of HPV vaccination on reducing cervical cancer incidence in HIV+ women.

Original languageEnglish (US)
Title of host publicationCancer Treatment and Research
PublisherSpringer International Publishing
Pages105-129
Number of pages25
DOIs
StatePublished - Jan 1 2019

Publication series

NameCancer Treatment and Research
Volume177
ISSN (Print)0927-3042

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Du, P. (2019). Human papillomavirus infection and cervical cancer in HIV+ women. In Cancer Treatment and Research (pp. 105-129). (Cancer Treatment and Research; Vol. 177). Springer International Publishing. https://doi.org/10.1007/978-3-030-03502-0_5